Publications

AIDs Journal Award

Co-last authors

  1. Tamura TJ, Choudhary MC, Deo R, Yousuf F, Gomez AN, Edelstein GE, Boucau J, Glover OT, Barry M, Gilbert RF, Reynolds Z, Li Y, Tien D, Vyas TD, Passell E, Su K, Drapkin S, Abar EG, Kawano Y, Sparks JA, Wallace ZS, Vyas JM, Shafer RW, Siedner MJ, Barczak AK, Lemieux JE, Li JZ; POSITIVES Study Team. Emerging SARS-CoV-2 Resistance After Antiviral Treatment. JAMA Netw Open. 2024. PDF
  2. Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Post-acute COVID-19 outcomes including participant-reported long COVID:amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial. EClinicalMedicine 2024. PDF
  3. Paul MK, Choudhary MC, Heaps AL, Deo R, Moisi D, Gordon KC, Mellors JW, Moser C, Klekotka P, Landay A, Currier JS, Eron JJ, Chew KW, Smith DM, Sieg SF, Parikh UM, Li JZ; ACTIV-2/A5401 Study Team. Impact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response. Pathog Immun. 2024. PDF
  4. Parikh UM, Heaps AL, Moisi D, Gordon KC, Mellors JW, Choudhary MC, Deo R, Moser C, Klekotka P, Landay AL, Currier JS, Eron JJ, Chew KW, Smith DM, Li JZ, Sieg SF; Team ACTIV-2/A5401 Study. Comparison Study of the Bio-Plex and Meso Scale Multiplexed SARS-CoV-2 Serology Assays Reveals Evidence of Diminished Host Antibody Responses to SARS-CoV-2 after Monoclonal Antibody Treatment. Pathog Immun. 2024. PDF
  5. Chew KW, Taiwo BO, Moser C, Daar ES, Wohl DA, Ritz J, Javan AC, Li JZ, Fischer W, Greninger AL, Bausch C, Luke T, Call R, Neytman G, Giganti MJ, Fletcher CV, Hughes MD, Eron JJ, Currier JS, Smith DM; ACTIV-2/A5401 Study Team. Safety and Efficacy of SAB-185 for Non-hospitalized Adults with COVID-19: A Randomized Clinical Trial. J Infect Dis. 2024. PDF
  6. Jilg N, Giganti MJ, Chew KW, Shaw-Saliba K, Ritz J, Moser C, Evering TH, Daar ES, Eron JJ, Currier JS, Hughes MD, Lane HC, Dewar R, Smith DM, Li JZ. Severe Acute Respiratory Syndrome Coronavirus 2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With Coronavirus Disease 2019. Clin Infect Dis. 2024. PDF
  7. Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial. Pathog Immun. 2024. PDF
  8. Phan T, Conway JM, Pagane N, Kreig J, Sambaturu N, Iyaniwura S, Li JZ, Ribeiro RM, Ke R, Perelson AS. Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion. PLoS Pathog. 2024. PDF
  9. Choudhary MC, Deo R, Evering TH, Chew KW, Giganti MJ, Moser C, Ritz J, Regan J, Flynn JP, Crain CR, Wohl DA, Currier JS, Eron JJ, Margolis D, Zhu Q, Zhon L, Ya L, Greninger AL, Hughes MD, Smith D, Daar ES, Li JZ. Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2024. PDF
  10. Phan T, Zitzmann C, Chew KW, Smith DM, Daar ES, Wohl DA, Eron JJ, Currier JS, Hughes MD, Choudhary MC, Deo R, Li JZ, Ribeiro RM, Ke R, Perelson AS; ACTIV-2/A5401 Study Team. Modeling the emergence of viral resistance for SARS- CoV-2 during treatment with an anti-spike monoclonal antibody. PLoS Pathog. 2024. PDF
  11. Li Y, Choudhary MC, Regan J, Boucau J, Nathan A, Speidel T, Liew MY, Edelstein GE, Kawano Y, Uddin R, Deo R, Marino C, Getz MA, Reynolds Z, Barry M, Gilbert RF, Tien D, Sagar S, Vyas TD, Flynn JP, Hammond SP, Novack LA, Choi B, Cernadas M, Wallace ZS, Sparks JA, Vyas JM, Seaman MS, Gaiha GD, Siedner MJ, Barczak AK, Lemieux JE, Li JZ. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci Transl Med. 2024. PDF
  12. Bender Ignacio RA, Chew KW, Moser C, Currier JS, Eron JJ, Javan AC, Giganti MJ, Aga E, Gibbs M, Tchouakam Kouekam H, Johnsson E, Esser MT, Hoover K, Neytman G, Newell M, Daar ES, Fischer W, Fletcher CV, Li JZ, Greninger AL, Coombs RW, Hughes MD, Smith D, Wohl DA; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)–2/A5401 Study Team. Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials. JAMA Netw Open. 2023. PDF 
  13. Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, Kittilson A, Melberg M, Crain CR, Traunbauer AK, Wong C, Fajnzylber J, Worrall DP, Rosenthal A, Jordan H, Jilg N, Kaseke C, Giguel F, Lian X, Deo R, Gillespie E, Chishti R, Abrha S, Adams T, Siagian A, Dorazio D, Anderson PL, Deeks SG, Lederman MM, Yawetz S, Kuritzkes DR, Lichterfeld MD, Sieg S, Tsibris A, Carrington M, Brumme ZL, Castillo-Mancilla JR, Engelman AN, Gaiha GD, Li JZ. Viral and host mediators of non-suppressible HIV-1 viremia. Nat Med. 2023. PDF
  14. Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Gilbert RF, Reynolds Z, Li Y, Tien D, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Barczak AK, Lemieux JE, Li JZ, Siedner MJ. SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study. Ann Intern Med. 2023. PDF
  15. Vecchio J, Regan J, Jiang Y, Li R, Romain H, Yousuf F, Adel T, Hall K, DaCosta JM, Yu X, Li JZ, Fofana IB. Viral and immunologic evaluation of smokers with severe COVID-19. Sci Rep. 2023. PDF
  16. Jagannathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Main MJ, Monk PD, Javan AC, Li JZ, Fletcher CV, McCarthy C, Wohl DA, Daar ES, Eron JJ, Currier JS, Singh U, Smith DM, Fischer W; ACTIV-2/A5401 Study Team. Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial. EClinicalMedicine. 2023. PDF
  17. Di Fenza R, Shetty NS, Gianni S, Parcha V, Giammatteo V, Safaee Fakhr B, Tornberg D, Wall O, Harbut P, Lai PS, Li JZ, Paganoni S, Cenci S, Mueller AL, Houle TT, Akeju O, Bittner EA, Bose S, Scott LK MD, Carroll RW, Ichinose F, Hedenstierna M, Arora P, Berra L. High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure due to COVID-19: A Multicenter Phase 2 Trial. Am J Respir Crit Care Med. 2023. PDF
  18. Irie WC, Chitneni P, Glynn TR, Allen W, Chai PR, Engelman AN, Hurtado R, Li JZ, Li P, Lockman S, Marcus JL, Ogunshola FJ, Rönn MM, Haberer J, Ghebremichael M, Ciaranello A; Harvard University Center for AIDS Research Diversity, Equity, and Inclusion Working Group. Pathways and Intersections: Multifaceted Approaches to Engage Individuals From Underrepresented and Marginalized Communities in HIV Research and Career Development. J Acquir Immune Defic Syndr. 2023. PDF
  19. Evering TH, Moser CB, Jilg N, Yeh E, Sanusi B, Wohl DA, Daar ES, Li JZ, Klekotka P, Javan AC, Eron JJ, Currier JS, Hughes MD, Smith DM, Chew KW; ACTIV-2/A5401 Study Team. Long COVID After Bamlanivimab Treatment. J Infect Dis. 2023. PDF
  20. Moser CB, Chew KW, Giganti MJ, Li JZ, Aga E, Ritz J, Greninger AL, Javan AC, Bender Ignacio R, Daar ES, Wohl DA, Currier JS, Eron JJ, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials. J Infect Dis. 2023. PDF
  21. Ribeiro RM, Choudhary MC, Deo R, Giganti MJ, Moser C, Ritz J, Greninger AL, Regan J, Flynn JP, Wohl DA, Currier JS, Eron JJ, Hughes MD, Smith DM, Chew KW, Daar ES, Perelson AS, Li JZ; ACTIV-2/A5401 Study Team. Variant-Specific Viral Kinetics in Acute COVID-19. J Infect Dis. 2023. PDF
  22. Li Y, Moser C, Aga E, Currier JS, Wohl DA, Daar ES, Ritz J, Greninger AL, Sieg S, Parikh UM, Coombs RW, Hughes MD, Eron JJ, Smith DM, Chew KW, Li JZ; ACTIV-2/A5401 Study Team. Immune Status and SARS-CoV-2 Viral Dynamics. J Infect Dis. 2023. PDF
  23. Giganti MJ, Chew KW, Eron JJ, Li JZ, Pinilla M, Moser C, Javan AC, Fischer WA, Klekotka P, Margolis D, Wohl DA, Coombs RW, Daar ES, Smith DM, Currier JS, Hughes MD; ACTIV-2/A5401 Study Team. Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19. J Infect Dis. 2023. PDF
  24. McNamara RP, Maron JS, Boucau J, Roy V, Webb NE, Bertera HL, Barczak AK, Positives Study Staff T, Franko N, Logue JK, Kemp M, Li JZ, Zhou L, Hsieh CL, McLellan JS, Siedner MJ, Seaman MS, Lemieux JE, Chu HY, Alter G. Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern. mBio. 2023. PDF
  25. Clancy CJ, Li JZ, Singh U, Sears CL. Transparent Reporting at the Journal of Infectious Diseases. J Infect Dis. 2023. PDF
  26. Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. One Week of Oral Camostat Versus Placebo in Non-Hospitalized Adults with Mild-to-Moderate COVID-19: A Randomized Controlled Phase 2 Trial. Clin Infect Dis. 2023. PDF
  27. Sanders-Beer BE, Archin NM, Brumme ZL, Busch MP, Deleage C, O’Doherty U, Hughes SH, Jerome KR, Jones RB, Karn J, Kearney MF, Keele BF, Kulpa DA, Laird GM, Li JZ, Lichterfeld MD, Nussenzweig MC, Persaud D, Yukl SA, Siliciano RF, Mellors JW. Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary. AIDS Res Hum Retroviruses. 2023. PDF 
  28. Esmaeilzadeh E, Etemad B, Lavine CL, Garneau L, Li Y, Regan J, Wong C, Sharaf R, Connick E, Volberding P, Sagar M, Seaman MS, Li JZ. Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption. Sci Transl Med. 2023. PDF
  29. Evering TH, Chew KW, Giganti MJ, Moser C, Pinilla M, Wohl DA, Currier JS, Eron JJ, Javan AC, Bender Ignacio R, Margolis D, Zhu Q, Ma J, Zhong L, Yan L, D’Andrea Nores U, Hoover K, Mocherla B, Choudhary MC, Deo R, Ritz J, Fischer WA, Fletcher CV, Li JZ, Hughes MD, Smith D, Daar ES; ACTIV-2/A5401 Study Team. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19. Ann Intern Med. 2023. PDF
  30. Deo R, Choudhary MC, Moser C, Ritz J, Daar ES, Wohl DA, Greninger AL, Eron JJ, Currier JS, Hughes MD, Smith DM, Chew KW, Li JZ; ACTIV-2/A5401 Study Team†. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. Ann Intern Med. 2023. PDF
  31. Etemad B, Sun X, Li Y, Melberg M, Moisi D, Gottlieb R, Ahmed H, Aga E, Bosch RJ, Acosta EP, Yuki Y, Martin MP, Carrington M, Gandhi RT, Jacobson JM, Volberding P, Connick E, Mitsuyasu R, Frank I, Saag M, Eron JJ, Skiest D, Margolis DM, Havlir D, Schooley RT, Lederman MM, Yu XG, Li JZ. HIV post-treatment controllers have distinct immunological and virological features. Proc Natl Acad Sci U S A. 2023. PDF
  32. Chen DY, Chin CV, Kenney D, Tavares AH, Khan N, Conway HL, Liu G, Choudhary MC, Gertje HP, O’Connell AK, Adams S, Kotton DN, Herrmann A, Ensser A, Connor JH, Bosmann M, Li JZ, Gack MU, Baker SC, Kirchdoerfer RN, Kataria Y, Crossland NA, Douam F, Saeed M. Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. Nature. 2023. PDF
  33. Wedrychowski A, Martin HA, Li Y, Telwatte S, Kadiyala GN, Melberg M, Etemad B, Connick E, Jacobson JM, Margolis DM, Skiest D, Volberding P, Hecht F, Deeks S, Wong JK, Li JZ, Yukl SA. Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control. J Virol. 2023. PDF
  34. Davis JM, Li JZ. The Promise and Peril of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Monoclonal Antibodies. Clin Infect Dis. 2022. PDF
  35. Li Y, Harrison LJ, Chew KW, Currier JS, Wohl DA, Daar ES, Evering TH, Wu R, Giganti M, Ritz J, Javan AC, Coombs R, Moser C, Hughes MD, Eron JJ, Smith DM, Li JZ. Nasal and Plasma SARS-CoV-2 RNA Levels are Associated with Timing of Symptom Resolution in the ACTIV-2 Trial of Non-hospitalized Adults with COVID-19. Clin Infect Dis. 2022 PDF
  36. Sears CL, Li JZ, Singh U. Turning the page: a welcome from the new leadership of the Journal of Infectious Diseases. J Infect Dis. 2022. PDF
  37. Moser C, Li JZ, Eron JJ, Aga E, Daar ES, Wohl DA, Coombs RW, Javan AC, Bender Ignacio RA, Jagannathan P, Ritz J, Sieg SF, Parikh UM, Hughes MD, Currier JS, Smith DM, Chew KW; ACTIV-2/A5401 Study Team. Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19. Open Forum Infect Dis. 2022. PDF
  38. Smith DM, Li JZ, Moser C, Yeh E, Currier JS, Chew KW, Hughes MD; ACTIV-2/A5401 Study Team. Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19. JAMA Netw Open. 2022. PDF
  39. Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes MD, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol. 2022. PDF
  40. Najjar D, Rainbow J, Sharma Timilsina S, Jolly P, de Puig H, Yafia M, Durr N, Sallum H, Alter G, Li JZ, Yu XG, Walt DR, Paradiso JA, Estrela P, Collins JJ, Ingber DE. A lab-on-a-chip for the concurrent electrochemical detection of SARS-CoV-2 RNA and anti-SARS-CoV-2 antibodies in saliva and plasma. Nat Biomed Eng. 2022. PDF
  41. Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, Ritz J, Giganti M, Javan AC, Li Y, Choudhary MC, Deo R, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS; ACTIV-2/A5401 Study Team; Hughes MD, Smith DM. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun. 2022. PDF
  42. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. 2022. PDF
  43. Seaman MS, Siedner MJ, Boucau J, Lavine CL, Ghantous F, Liew MY, Mathews JI, Singh A, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Lipiner T, Kittilson A, Melberg M, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Goldberg MB, Luban J, Li JZ, Barczak AK, Lemieux JE. Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant. JCI Insight. 2022. PDF
  44. Sun X, Gao C, Zhao K, Yang Y, Rassadkina Y, Fajnzylber J, Regan J, Li JZ, Lichterfeld M, Yu XG. Immune-profiling of SARS-CoV-2 viremic patients reveals dysregulated innate immune responses. Front Immunol. 2022. PDF.
  45. Choudhary MC, Li JZ. Uncovering hidden sources of SARS-CoV-2 viral evolution: A call to action. Transpl Infect Dis. 2022. PDF.
  46. Boucau J, Chew KW, Choudhary MC, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA 2nd, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM; POSITIVES study team, Li JZ*, Barczak AK*; ACTIV-2/A5401 Study Team. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. Cell Rep Med. 2022. PDF.
  47. Boucau J, Marino C, Regan J, Uddin R, Choudhary MC, Flynn JP, Chen G, Stuckwisch AM, Mathews J, Liew MY, Singh A, Lipiner T, Kittilson A, Melberg M, Li Y, Gilbert RF, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Goldberg MB, Vyas JM, Li JZ*, Lemieux JE*, Siedner MJ*, Barczak AK*. Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection. N Engl J Med. 2022. PDF.
  48. Wang C, Li Y, Kaplonek P, Gentili M, Fischinger S, Bowman KA, Sade-Feldman M, Kays KR, Regan J, Flynn JP, Goldberg MB, Hacohen N, Filbin MR, Lauffenburger DA, Alter G, Li JZ. The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia. mBio. 2022. PDF.
  49. Boucau J, Uddin R, Marino C, Regan J, Flynn JP, Choudhary MC, Chen G, Stuckwisch AM, Mathews J, Liew MY, Singh A, Reynolds Z, Iyer SL, Chamberlin GC, Vyas TD, Vyas JM, Turbett SE, Li JZ*, Lemieux JE*, Barczak AK*, Siedner MJ*. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19. Clin Infect Dis. 2022. PDF.
  50. Li Y, Li JZ. SARS-CoV-2 Virology. Infect Dis Clin North Am. 2022. PDF.
  51. Kaneko N, Boucau J, Kuo HH, Perugino C, Mahajan VS, Farmer JR, Liu H, Diefenbach TJ, Piechocka-Trocha A, Lefteri K, Waring MT, Premo KR, Walker BD, Li JZ, Gaiha G, Yu XG, Lichterfeld M, Padera RF Jr, Pillai S. Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19. Clin Immunol. 2022. PDF.
  52. Silverstein NJ, Wang Y, Manickas-Hill Z, Carbone C, Dauphin A, Boribong BP, Loiselle M, Davis J, Leonard MM, Kuri-Cervantes L, MGH COVID-19 Collection & Processing Team, Meyer NJ, Betts MR, Li JZ, Walker B, Yu XG, Yonker LM, Luban J. Innate lymphoid cells and COVID-19 severity in SARS-CoV-2 infection. eLife 2022. PDF.
  53. Regan J, Flynn JP, Choudhary MC, Uddin R, Lemieux J, Boucau J, Bhattacharyya RP, Barczak AK, Li JZ*, Siedner MJ*. Detection of the Omicron Variant Virus With the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay. Open Forum Infect Dis. 2022. PDF.
  54. Cerecedo-Lopez CD, Bernstock JD, Dmytriw AA, Chen JA, Chalif JI, Gupta S, Driver J, Huang K, Stanley SE, Li JZ, Chi J, Lu Y. Spontaneous intramedullary abscesses caused by Streptococcus anginosus: two case reports and review of the literature.  BMC Infect Dis. 2022. PDF.
  55. Li JZ, Gandhi RT. Realizing the Potential of Anti-SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management. JAMA. 2022. PDF.
  56. Shook LL, Brigida S, Regan J, Flynn JP, Mohammadi A, Etemad B, Siegel MR, Clapp MA, Li JZ, Roberts DJ, Edlow AG. SARS-CoV-2 Placentitis Associated with B.1.617.2 (Delta) Variant and Fetal Distress or Demise. J Infect Dis. 2022. PDF.
  57. Brijkumar J, Edwards JA, Johnson BA, Ordonez C, Sunpath H, Lee M, Dudgeon MR, Rautman L, Pillay S, Moodley P, Sun YV, Castillo-Mancilla J, Li JZ, Kuritzkes DR, Moosa MYS, Marconi VC. Comparing effectiveness of first-line antiretroviral therapy between peri-urban and rural clinics in KwaZulu-Natal, South Africa. HIV Med. 2022.
  58. Siedner MJ, Boucau J, Gilbert RF, Uddin  R, Luu J, Haneuse S, Vyas T, Reynolds Z, Iyer S, Chamberlin GC, Goldstein RH, North CM, Sacks CA, Regan J, Flynn JP, Choudhary MC, Vyas JM, Barczak AK, Lemieux JE, Li JZ. Duration of viral shedding and culture positivity with post-vaccination SARS-CoV-2 delta variant infections. JCI Insight. 2021. PDF.
  59. Bordt EA, Shook LL, Atyeo C, Pullen KM, De Guzman RM, Meinsohn M-C, Chauvin M, Fischinger S, Yockey LJ, James K, Lima R, Yonker LM, Fasano A, Brigida S, Bebell LM, Roberts DJ, Pepin D, Huh JR, Bilbo SD, Li JZ, Kaimal A, Schust DJ, Gray KJ, Lauffenburger D, Alter G, Edlow AG. Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses. Sci Transl Med. 2021. PDF.
  60. Yonker LM, Boucau J, Regan J, Choudhary MC, Burns MD, Young N, Farkas EJ, Davis JP, Moschovis PP, Kinane TB, Fasano A, Neilan AM, Li JZ*, Barczak AK*. Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. J Infect Dis. 2021. PDF.
  61. Raines NH, Cheung MD, Wilson LS, Edberg JC, Erdmann NB, Schmaier AA, Berryhill TF, Manickas-Hill Z, Li JZ, Yu XG, Agarwal A, Barnes S, Parikh SM. Nicotinamide Adenine Dinucleotide Biosynthetic Impairment and Urinary Metabolomic Alterations Observed in Hospitalized Adults With COVID-19-Related Acute Kidney Injury. Kidney Int Rep. 2021. PDF.
  62. Matute JD, Finander B, Pepin D, Ai X, Smith NP, Li JZ, Edlow AG, Villani A-C, Lerou PH, Kalish BT. Single-cell immunophenotyping of the fetal immune response to maternal SARS-CoV-2 infection in late gestation. Pediatr Res. 2021. PDF.
  63. Galvan-Pena S, Leon J, Chowdhary K, Michelson DA, Vijaykumar B, Yang L, Magnuson AM, Chen F, Manickas-Hill Z, Piechocka-Trocha A, Worrall DP, Hall KE, Ghebremichael M, Walker BD, Li JZ, Yu XG, MGH COVID-19 Collection & Processing Team, Mathis D, Benoist C. Profound Treg perturbations correlate with COVID-19 severity. PNAS. 2021. PDF.
  64. Silva FSR, Erdogmus E, Shokr A, Kandula H, Thirumalaraju P, Kanakasabapathy MK, Hardie JM, Pacheco LGC, Li JZ, Kuritzkes DR, Shafiee H. SARS-CoV-2 RNA Detection by a Cellphone-Based Amplification-Free System with CRISPR/CAS-Dependent Enzymatic (CASCADE) Assay. Adv Mater Technol. 2021. PDF.
  65. Regan J, Flynn JP, Rosenthal A, Jordan H, Li Y, Chishti R, Giguel F, Corry H, Coxen K, Fajnzylber J, Gillespie E, Kuritzkes DR, Hacohen N, Goldberg MB, Filbin MR, Yu XG, Baden L, Ribeiro RM, Perelson AS, Conway JM, Li JZ, MGH COVID-19 Collection & Processing Teams. Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infect Dis. 2021. PDF.
  66. North CM, Barczak A, Goldstein RH, Healy BC, Finkelstein DM, Ding DD, Kim A, Boucau J, Shaw B, Gilbert RF, Vyas T, Reynolds Z, Siddle KJ, MacInnis BL, Regan J, Flynn JP, Choudhary MC, Vyas JM, Laskowski K, Dighe AS, Lemieux JE, Li JZ, Baden LR, Siedner MJ, Woolley AE, Sacks CA. Determining the Incidence of Asymptomatic SARS-CoV-2 among Early Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers before, during, and after Vaccination [DISCOVER-COVID-19]. Clin Infect Dis. 2021. PDF.
  67. Shook LL, Bordt EA, Meinsohn M-C, Pepin D, De Guzman RM, Brigida S, Yockey LJ, James KE, Sullivan MW, Bebell LM, Roberts DJ, Kaimal AJ, Li JZ, Schust D, Gray KJ, Edlow AG. Placental expression of ACE2 and TMPRSS2 in maternal SARS-CoV-2 infection: are placental defenses mediated by fetal sex? J Infect Dis. 2021. PDF.
  68. Leisman DE, Mehta A, Li Y, Kays KR, Li JZ, Filbin MR, Goldberg MB. Vasopressin infusion in COVID-19 critical illness is not associated with impaired viral clearance: a pilot study. Br J Anaesth. 2021. PDF.
  69. Das Adhikari U, Eng G, Farcasanu M, Avena LE, Choudhary MC, Triant VA, Flagg M, Schiff AE, Gomez I, Froehle LM, Diefenbach TJ, Ronsard L, Lingwood D, Lee GC, Alireza Rabi S, Erstad D, Velmahos G, Li JZ, Hodin R, Stone JR, Honko AN, Griffiths A, Yilmaz OH, Kwon DS. Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA is Associated With Decreased Coronavirus Disease 2019 (COVID-19) Survival. Clin Infect Dis. 2021. PDF.
  70. Kim M-H, Salloum S, Wang JY, Wong LP, Regan J, Lefteri K, Manickas-Hill Z, Gao C, Li JZ, Sadreyev RI, Yu XG, Chung RT. Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity. J Infect Dis. 2021. PDF.
  71. Li JZ, Blankson JN. How elite controllers and posttreatment controllers inform our search for an HIV-1 cure. J Clin Invest. 2021. PDF.
  72. Li JZ, Aga E, Bosch R, Pilkinton M, Kroon E, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Anaworanich J, Coombs R, Mellors J, Landay A, Macatangay B, Deeks S, Gandhi RT, Smith DM. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clin Infect Dis. 2021. PDF.
  73. Fajnzylber J, Sharaf R, Hutchinson JN, Aga E, Bosch RJ, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest DJ, Margolis D, Sneller MC, Little SJ, Gulick RM, Mellors JW, Gandhi RT, Schooley RT, Henry K, Tebas P, Deeks S, Chun T-W, Collier AC, Hecht FM, Li JZ. Frequency of Post Treatment Control Varies by ART Restart and Viral Load Criteria. AIDS. 2021. PDF.
  74. Hahn G, Wu CM, Lee S, Lutz SM, Khurana S, Baden LR, Haneuse S, Qiao D, Hecker J, DeMeo DL, Tanzi RE, Choudhary MC, Etemad B, Mohammadi A, Esmaeilzadeh E, Cho MH, Li JZ, Randolph AG, Laird NM, Weiss ST, Silverman EK, Ribbeck K, Lange C. Genome-wide association analysis of COVID-19 mortality risk in SARS-CoV-2 genomes identifies mutation in the SARS-CoV-2 spike protein that colocalizes with P.1 of the Brazilian strain. Genet Epidemiol. 2021. PDF.
  75. Giron LB, Palmer CS, Liu Q, Yin X, Papsavvas E, Sharaf R, Etemad B, Damra M, Goldman AR, Tang H-Y, Johnston R, Mounzer K, Kostman JR, Tebas P, Landay A, Montaner LJ, Jacobson JM, Li JZ, Abdel-Mohsen M. Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. Nat Commun. 2021. PDF.
  76. Li Y, Schneider AM, Mehta A, Sade-Feldman M, Kays KR, Gentili M, Charland NC, Gonye ALK, Gushterova I, Khanna HK, LaSalle TJ, Lavin-Parsons KM, Lilley BM, Lodenstein CL, Manakongtreecheep K, Margolin JD, McKaig BN, Parry BA, Rojas-Lopex M, Russo BC, Sharma N, Tantivit J, Thomas MF, Regan J, Flynn JP, Villani A-C, Hacohen N, Goldberg MB, Filbin MR, Li JZ. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. J Clin Invest. 2021. PDF.
  77. Harb H, Benamar M, Lai PS, Contini P, Griffith JW, Crestani E, Schmitz-Abe K, Chen Q, Fong J, Marri L, Filaci G, Del Zotto G, Pishesha N, Kolifrath S, Broggi A, Ghosh S, Yusuf Gelmez M, Betul Oktelik F, Aktas Cetin E, Kiykim A, Kose M, Wang Z, Cui Y, Yu XG, Li JZ, Berra L, Stephen-Victor E, Charbonnier L-M, Zanoni I, Ploegh H, Deniz G, De Palma R, Chatila TA. Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. Immunity. 2021. PDF.
  78. Choudhary MC, Crain CR, Qiu X, Hanage W, Li JZ. SARS-CoV-2 Sequence Characteristics of COVID-19 Persistence and Reinfection. Clin Infect Dis. 2021. PDF.
  79. Conway JM, Meily P, Li JZ, Perelson AS. Unified model of short- and long-term HIV viral rebound for clinical trial planning. J R Soc Interface. 2021. PDF.
  80. Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusic V, Choudhary MC, Regan J, Li JZ, Griffiths A, Abraham J. SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell. 2021. PDF.
  81. Ter-Ovanesyan D, Gilboa T, Lazarovits R, Rosenthal A, Yu X, Li JZ, Church GM, Walt DR. Ultrasensitive Measurement of Both SARS-CoV-2 RNA and Antibodies from Saliva. Anal Chem. 2021. PDF.
  82. Bartsch YC, Loos C, Rossignol E, Fajnzylber JM, Yuan D, Avihingsanon A, Ubolyam S, Jupimai T, Hirschel B, Ananworanich J, Lauffenburger DA, Li JZ, Alter G, Julg B. Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. mBio. 2021. PDF.
  83. Li JZ, Stella N, Choudhary MC, Javed A, Rodriguez K, Ribaudo H, Moosa M-Y, Brijkumar J, Pillay S, Sunpath H, Noguera-Julian M, Paredes R, Johnson B, Edwards A, Marconi VC, Kuritzkes DR. Impact of pre-existing drug resistance on risk of virological failure in South Africa. J Antimicrob Chemother. 2021. PDF.
  84. Li Y, Etemad B, Dele-Oni R, Sharaf R, Gao CC, Lichterfeld M, Li JZ. Drug Resistance Mutations in HIV Provirus are Associated with Defective Proviral Genomes with Hypermutation. AIDS. 2021. PDF. (Editorial: Richman, DD. Disregarding drug resistance mutations without peril. AIDS. 2021. PDF).
  85. Li JZ, Gandhi RT. The Search for an HIV Cure: Where Do We Go From Here? J Infect Dis. 2021. PDF.
  86. Li Y, Mohammadi A, Li JZ. Challenges and Promise of Human Immunodeficiency Virus Remission. J Infect Dis. 2021. PDF.
  87. Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, Li JZ, Bloom JD. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021. PDF.
  88. Li Y, Regan J, Fajnzylber J, Coxen K, Corry H, Wong C, Rosenthal A, Atyeo C, Fischinger S, Gillespie E, Chishti R, Baden L, Yu XG, Alter G, Kim A, Li JZ. Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19. Hepatol Commun. 2020. PDF.
  89. Shokr A, Pacheco LGC, Thirumalaraju P, Kanakasabapathy MK, Gandhi J, Kartik D, Silva FSR, Erdogmus E, Kandula H, Luo S, Yu XG, Chung RT, Li JZ, Kuritzkes DR, Shafiee H. Mobile Health (mHealth) Viral Diagnostics Enabled with Adaptive Adversarial Learning. ACS Nano. 2020.
  90. Edlow AG, Li JZ, Collier AY, Atyeo C, James KE, Boatin AA, Gray KJ, Bordt EA, Shook LL, Yonker LM, Fasano A, Diouf K, Croul N, Devane S, Yockey LJ, Lima R, Shui J, Matute JD, Lerou PH, Akinwunmi BO, Schmidt A, Feldman J, Hauser BM, Caradonna TM, De la Flor D, D’Avino P, Regan J, Corry H, Coxen K, Fajnzylber J, Pepin D, Seaman MS, Barouch DH, Walker BD, Yu XG, Kaimal AJ, Roberts DJ, Alter G. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Netw Open. 2020. PDF.
  91. Qian J, Boswell SA, Chidley C, Lu Z-X, Pettit ME, Gaudio BL, Fajnzylber JM, Ingram RT, Ward RH, Li JZ, Springer M. An enhanced isothermal amplification assay for viral detection. Nat Commun. 2020. PDF.
  92. Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, Leng Y, Robinson ML, Sie BM, Li MZ, Chen Y, Logue J, Zuiani A, McCulloch D, Lelis FJN, Henson S, Monaco DR, Travers M, Habibi S, Clarke WA, Caturegli P, Laeyendecker O, Piechocka-Trocha A, Li JZ, Khatri A, Chu HY, MGH COVID-19 Collection & Processing Team, Villani A-C, Kays K, Goldberg MB, Hacohen N, Filbin MR, Yu XG, Walker BD, Wesemann DR, Larman HB, Lederer JA, Elledge SJ. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020. PDF.
  93. Siddiqi HK, Weber B, Zhou G, Regan J, Fajnzylber J, Coxen K, Corry H, Yu XG, DiCarli M, Li JZ, Bhatt DL. Increased prevalence of myocardial injury in patients with SARS-CoV-2 viremia. Am J Med. 2020. PDF.
  94. Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J, Bowman K, Das Adhikari U, Winkler ML, Mueller AA, Hsu TYT, Desjardins M, Baden LR, Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZ. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020. PDF. (Supplementary Appendix PDF).
  95. Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, Worrall D, Giguel F, Piechocka-Trocha A, Atyeo C, Fischinger S, Chan A, Flaherty KT, Hall K, Dougan M, Ryan ET, Gillespie E, Chishti R, Li Y, Jilg N, Hanidziar D, Baron RM, Baden L, Tsibris AM, Armstrong KA, Kuritzkes DR, Alter G, Walker BD, Yu X, Li JZ. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020. PDF. (Supplementary Information PDF). One of the top 50 most read Nat Commun SARS-CoV-2 papers in 2020
  96. Yonker LM, Neilan AM, Bartsch Y, Patel AB, Regan J, Arya P, Gootkind E, Park G, Hardcastle M, St. John A, Appleman L, Chiu ML, Fialkowski A, De la Flor D, Lima R, Bordt EA, Yockey LJ, D’Avino P, Fischinger S, Shui JE, Lerou PH, Bonventre JV, Yu XG, Ryan ET, Bassett IV, Irimia D, Edlow AG, Alter G, Li JZ, Fasano A. Pediatric SARS-CoV-2: Clinical Presentation, Infectivity, and Immune Responses. J Pediatr. 2020. PDF
  97. Kaneko N, Kuo HH, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, Piechocka-Trocha A, Lefteri K, Osborn M, Bals J, Bartsch YC, Bonheur N, Caradonna TM, Chevalier J, Chowdhury F, Diefenbach TJ, Einkauf K, Fallon J, Feldman J, Finn KK, Garcia-Broncano P, Adijaya Hartana C, Hauser BM, Jiang C, Kaplonek P, Karpell M, Koscher EC, Lian X, Liu H, Liu J, Ly NL, Michell AR, Rassadkina Y, Seiger K, Sessa L, Shin S, Singh N, Sun W, Sun X, Ticheli HJ, Waring MT, Zhu AL, Alter G, Li JZ, Lingwood D, Schmidt AG, Lichterfeld M, Walker BD, Yu X, Padera RF, Pillai S. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell. 2020. PDF
  98. Mohammadi A, Esmaeilzadeh E, Li Y, Bosch RJ, Li JZ. SARS-CoV-2 Detection in Different Respiratory Sites: a Systematic Review and Meta-Analysis. EBioMedicine. 2020. PDF
  99. Li JZ, Yu XG. Overcoming Challenges in COVID-19 Translational Research. J Infect Dis. 2020. PDF
  100. Jilg N, Garcia-Broncano P, Peluso M, Segal FP, Bosch RJ, Roberts-Toler C, Chen SMY, Van Dam CN, Keefer MC, Kuritzkes DR, Landay AL, Deeks S, Yu XG, Sax PE, Li JZ. HIV Controllers Maintain Viral Suppression Despite Waning T-Cell Responses on ART. J Infect Dis. 2020. PDF
  101. Ramirez JA, Maddali MV, Budak JZ, Li JZ, Lampiris H, Shah M. Evaluating the Concordance of Clinician Antiretroviral Prescribing Practices and HIV-ASSIST, an Online Clinical Decision Support Tool. J Gen Intern Med. 2020. PDF
  102. Andrade VM, Mavian C, Babic D, Cordeiro T, Sharkey M, Barrios L, Brander C, Martinez-Picado J, Dalmau J, Llano A, Li JZ, Jacobson J, Lavine CL, Seaman MS, Salemi M, Stevenson M. A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption. Proc Natl Acad Sci USA. 2020. PDF
  103. Ramirez JA, Maddali MV, Nematollahi S, Li JZ, Shah M. New Strategies in Clinical Guideline Delivery: Randomized trial of online, interactive decision-support versus guidelines for HIV treatment selection by trainees. Clin Infect Dis. 2020. PDF
  104. Maddali MV, Mehtani NJ, Converse C, Kapoor S, Pham P, Li JZ, Shah M. Development and Validation of HIV-ASSIST, an Online, Educational, Clinical Decision Support Tool to Guide Patient-Centered ARV Regimen Selection. J Acquir Immune Defic Syndr. 2019. PDF
  105. Etemad B, Esmaeilzadeh E, Li JZ. Learning From the Exceptions: HIV Remission in Post-treatment Controllers. Front in Immun. 2019. PDF
  106. Jilg N, Li JZ. On the Road to a HIV Cure. Infect Dis Clin. 2019. PDF
  107. Conway JW, Perelson AS, Li JZ. Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers. PLoS Comput Biol. 2019. PDF
  108. Li JZ, Segal FP, Bosch RJ, Lalama CM, Roberts-Toler C, Delagreverie H, Getz R, Garcia-Broncano P, Kinslow J, Tressler R, Van Dam CN, Keefer M, Carrington M, Lichterfeld M, Kuritzkes D, Yu XG, Landay A, Sax PE; AIDS Clinical Trials Group Study A5308 Team. ART reduces T cell activation and immune exhaustion markers in HIV controllers. Clin Infect Dis. 2019. PDF
  109. Li JZ, Sax PE, Marconi VC, Fajnzylber J, Berzins B, Nyaku AN, Fichtenbaum CJ, Wilkin T, Benson CA, Koletar SL, Lorenzo-Redondo R, Taiwo BO. No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. Open Forum Infect Dis. 2019. PDF
  110. Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials – report of a consensus meeting. Lancet HIV. 2019. PDF
  111. Einkauf KB, Lee GQ, Gao C, Sharaf R, Sun X, Hua S, Chen SMY, Jiang C, Lian X, Chowdhury FZ, Rosenberg ES, Chun TW, Li JZ, Yu XG, Lichterfeld M. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J Clin Invest. 2019. PDF
  112. Namazi G, Fajnzylber JM, Aga E, Bosch R, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith D, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks S, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ. The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies. J Infect Dis. 2018. PDF . One of the top 10% most downloaded JID papers over the past 2 years  
  113. Scully EP, Rutishauser RL, Simoneau CR, Delagrèverie H, Euler Z, Thanh C, Li JZ, Hartig H, Bakkour S, Busch M, Alter G, Marty FM, Wang CC, Deeks SG, Lorch J, Henrich TJ. Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Ann Oncol. 2018. PDF
  114. Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018. PDF
  115. Jiang J, Meng S, Huang S, Ruan Y, Lu X, Li JZ, Wu N, Huang J, Xie Z, Liang B, Deng J, Zhou B, Chen X, Ning C, Liao Y, Wei W, Lai J, Ye L, Wu F, Liang H. Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. Clin Microbiol Infect. 2018.
  116. Salantes B, Zheng Y, Mampe F, Srivastava T, Beg S, Lai J, Li JZ, Tressler RL, Koup RA, Hoxie J, Abdel-Mohsen M, Sherrill-Mix S, McCormick K, Overton T, Bushman FD, Learn GH, Siliciano RF, Siliciano JM, Tebas P, Bar KJ. HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J Clin Invest. 2018. PDF
  117. Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O’Doherty U, Li JZ. Effect of short-term ART interruption on levels of integrated HIV DNA. J Virol. 2018. PDF
  118. Wen Y, Bar KJ, Li JZ, Lessons learned from HIV antiretroviral treatment interruption trials. Curr Opin HIV AIDS. 2018. PDF
  119. Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE. Dolutegravir plus lamivudine maintain HIV-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis. 2017.
  120. Stella-Ascariz N, Arribas JR, Paredes R, Li JZ. The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure. J Infect Dis. 2017. PDF
  121. Park YJ, Etemad B, Ahmed H, Naranbhai V, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Carrington M, Li JZ. Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. Pathog Immun. 2017. PDF
  122. Kanakasabapathy MK, Pandya HJ, Draz MS, Chug MK, Sadasivam M, Kumar S, Etemad B, Yogesh V, Safavieh M, Asghar W, Li JZ, Tsibris AM, Kuritzkes DR, Shafiee H. Rapid, label-free CD4 testing using a smartphone compatible device. Lab Chip 2017.
  123. Henrich TJ, Hobbs KS, Hanhauser E, Scully E, Hogan LE, Robles YP, Leadabrand KS, Marty FM, Palmer CD, Jost S, Körner C, Li JZ, Gandhi RT, Hamdan A, Abramson J, LaCasce AS, Kuritzkes DR. Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. J Infect Dis. 2017.
  124. Sharaf RR, Li JZ. The Alphabet Soup of HIV Reservoir Markers. Curr HIV/AIDS Rep. 2017. PDF
  125. Wen Y, Li JZ. Post-treatment HIV controllers or spontaneous controllers in disguise? AIDS. 2017. PDF 
  126. Jumare J, Sunshine S, Ahmed H, El-Kamary SS, Magder L, Hungerford L, Burdo T, Eyzaguirre LM, Umlauf A, Cherner M, Abimiku A, Charurat M, Li JZ, Blattner WA, Royal W 3rd. Peripheral blood lymphocyte HIV DNA levels correlate with HIV associated neurocognitivedisorders in Nigeria. J Neurovirol. 2017. PDF
  127. Delagrèverie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ. Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open Forum Infect Dis. 2016. PDF
  128. Tang JC, Drokhlyansky E, Etemad B, Rudolph S,  Guo B, Wang S, Ellis EG, Li JZ, Cepko CL. Detection and manipulation of live antigen-expressing cells using conditionally stable nanobodies. eLife. 2016. PDF
  129. Sunshine S, Kirchner R, Amr SS, Mansur L, Shakhbatyan R, Kim M, Bosque A, Siliciano RF, Planelles V, Hofmann O, Ho Sui S, Li JZ. HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay. J Virol. 2016. PDF
  130. Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Li JZ. Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. J Acquir Immune Defic Syndr. 2016. PDF
  131. Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS. 2016. PDF .Most cited AIDS basic science paper of 2018
  132. Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, Lederman M, Gandhi RT, Keele BF, Li JZ. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy. J Virol. 2015. PDF
  133. Ndhlovu ZM, Stampouloglou E, Cesa K, Mavrothalassitis O, Alvino DM, Li JZ, Wilton S, Karel D, Piechocka-Trocha A, Chen H, Pereyra F, Walker BD. The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers. J Virol. 2015. PDF
  134. Konstantopoulos C, Ribaudo H, Ragland K, Bangsberg DR, Li JZ. Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia. Open Forum Infect Dis. 2015. PDF
  135. Li JZ, Arnold KB, Lo J, Dugast AS, Plants J, Ribaudo HJ, Cesa K, Heisey A, Kuritzkes DR, Lauffenburger DA, Alter G, Landay A, Grinspoon S, Pereyra F. Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics. Open Forum Infect Dis. 2015. PDF
  136. Li JZ, Smith DM, Mellors JW. The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS. 2015. PDF
  137. Li JZ, Heisey A, Ahmed H, Wang H, Zheng L, Carrington M, Wrin T, Schooley RT, Lederman MM, Kuritzkes DR. Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study. AIDS. 2014. PDF
  138. Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, Robles YP, Davis BT, Li JZ, Heisey A, Hill AL, Busch MP, Armand P, Soiffer RJ, Altfeld M, Kuritzkes DR. Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases. Ann Intern Med. 2014. PDF
  139. Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M. Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. J Virol. 2014. PDF
  140. Al-Hajjar SH, Frayha HH, Al-Hazmi M, Batawi R, McIntosh K, Sax PE, Al-Thawadi S, Al-Jumaah S, Busch MP, Hanhauser E, Kuritzkes DR, Li JZ, Henrich TJ. Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion. AIDS. 2014. PDF
  141. Li JZ, Chapman B, Charlebois P, Hofmann O, Weiner B, Porter AJ, Samuel R, Vardhanabhuti S, Zheng L, Eron J, Taiwo B, Zody MC, Henn MR, Kuritzkes DR, Hide W, Wilson CC, Berzins BI, Acosta EP, Bastow B, Kim PS, Read SW, Janik J, Meres DS, Lederman MM, Mong-Kryspin L, Shaw KE, Zimmerman LG, Leavitt R, De La Rosa G, Jennings A. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. PLoS One. 2014. PDF
  142. Li JZ, Gallien S, Ribaudo H, Heisey A, Bangsberg DR, Kuritzkes DR. Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS. 2014. PDF
  143. Li JZ. HIV-1 Drug-Resistant Minority Variants: Sweating the Small Stuff. J Infect Dis. 2013. PDF
  144. Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, Kuritzkes DR. Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation. J Infect Dis. 2013. PDF
  145. Li JZ, Kuritzkes DR. Clinical Implications of HIV-1 Minority Variants. Clin Infect Dis. 2013. PDF
  146. Huang J, Jiang J, Li JZ, Yang X, Deng W, Abdullah AS, Qin B, Upur H, Zhong C, Wang Q, Wang Q, Ruan Y, Zou Y, Ye L, Xie P, Wei F, Xu N, Wei B, Liang H. Prevalence and Correlates of Sexual Risk Behaviors Among Drug Users in Western China: Implications for HIV Transmission. AIDS Res Hum Retroviruses. 2013. PDF
  147. Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR. Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis. 2013. PDF
  148. Henrich TJ, Gallien S, Li JZ, Pereyra F, Kuritzkes DR. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods. 2012. PDF
  149. Li JZ, Christensen JA, Wang H, Spritzler J, Kuritzkes DR. Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption. J Acquir Immune Defic Syndr. 2012. PDF
  150. Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, Hatano H. Prevalence and Significance of HIV-1 Drug Resistance Mutations among Patients on Antiretroviral Therapy with Detectable Low-Level Viremia. Antimicrob Agents Chemother. 2012. PDF
  151. Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik K, Walker BD, Schooley RT, Kuritzkes DR. Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One. 2012. PDF
  152. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS. 2012. PDF
  153. Chew KW, Yen IH, Li JZ, Winston LG. Predictors of pneumonia severity in HIV-infected adults admitted to an Urban public hospital. AIDS Patient Care STDS. 2011. PDF
  154. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011. PDF
  155. Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, Lederman MM, Carrington M, Walker BD, Schooley RT, Kuritzkes DR. Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis. 2011. PDF
  156. Henrich TJ, Li JZ, Felsenstein D, Kotton CN, Plenge RM, Pereyra F, Marty FM, Lin NH, Grazioso P, Crochiere DM, Eggers D, Kuritzkes DR, Tsibris AM. Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis. 2010. PDF
  157. Tucker JD, Li JZ, Robbins GK, Davis BT, Lobo AM, Kunkel J, Papaliodis GN, Durand ML, Felsenstein D. Ocular syphilis among HIV-infected patients: a systematic analysis of the literature. Sex Transm Infect. 2011. PDF
  158. Li JZ, Tucker JD, Lobo AM, Marra CM, Davis BT, Papaliodis GN, Felsenstein D, Durand ML, Yawetz S, Robbins GK. Ocular syphilis among HIV-infected individuals. Clin Infect Dis. 2010. PDF
  159. Li JZ, Sax PE. AZT or tenofovir for patients with the K65R mutation? J Watch AIDS Clin Care. 2010. PDF
  160. Li JZ, Sax PE. HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person. AIDS Read. 2009. PDF
  161. Li JZ, Huen W. Images in clinical medicine. Calciphylaxis with arterial calcification. N Engl J Med. 2007. PDF
  162. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007. PDF
  163. Li JZ, Mack EC, Levy JA. Virucidal efficacy of soap and water against human immunodeficiency virus in genital secretions. Antimicrob Agents Chemother. 2003. PDF